A well-known, four-year study found popular arthritis drug Celebrex no more dangerous for the heart than older drugs in its same classification - commonly called NSAIDs. Now, a big-data analysis of patient records at Vanderbilt University has found a link specifically between Celebrex and heart valve calcification.

Patients with Duchenne muscular dystrophy (DMD) have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects. The investigational drug edasalonexent, an oral NF-κB inhibitor, has the potential to slow the progression of the disease for all patients with DMD.

Salt apparently affects allergic immune reactions. A team working with Prof. Christina Zielinski at the Technical University of Munich (TUM) has demonstrated in cell cultures that salt leads to the formation of Th2 cells. These immune cells are active in allergic conditions such as atopic dermatitis. The team also detected elevated salt concentrations in the skin of patients.

With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A Northwestern University team led by nanotechnology pioneer Chad A. Mirkin has developed a direct route to optimize these challenging particles,

A pilot program using several clinical decision support tools in the outpatient setting to treat and educate stable ischemic heart disease patients has shown success in improving angina in these patients. Findings from the Florida Cardiovascular Quality Network study were presented at the American College of Cardiology's Cardiovascular Summit in Orlando. The conference brings together top experts to discuss and review innovative, relevant cardiovascular management and leadership strategies.

A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published today in Science Translational Medicine. The therapeutic approach involves modifying human platelets to create "decoys" that are still capable of binding to some cells but will not aggregate or carry out the other normal platelet functions, including chemical signaling associated with the clotting process.

When normal cells grow, divide or do any job in the body, they do so in response to a whole slew of internal sensors that measure nutrients and energy supply, and environmental cues that inform what happens outside the cell. A protein called mTOR receives information from these signals and then directs the cell to take action.